{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-000570","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.315462+00:00","generated_at":"2026-05-27T22:26:45.514192+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dermata and Revance enter clinical trial collaboration for Xyngari with Daxxify in hyperhidrosis","bullets":["Dermata and Revance will collaborate on a Phase 2a trial of topical Xyngari with Daxxify for moderate-to-severe axillary hyperhidrosis.","Trial expected to enroll ~48 patients across US sites; randomized 1:1:1:1, double-blind, placebo-controlled, 16-week evaluation.","Primary endpoints: ≥50% reduction in gravimetric sweat, absolute change in sweat production, and sweat <50mg.","If successful, parties may explore additional indications; Xyngari is currently in Phase 3 for acne; Daxxify approved for glabellar lines and cervical dystonia.","Potential to be first approved needle-free intradermal delivery of a botulinum toxin product."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-000570","json":"https://secwatch.observer/filing/0001654954-25-000570.json","markdown":"https://secwatch.observer/filing/0001654954-25-000570.md","text":"https://secwatch.observer/filing/0001654954-25-000570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000570/0001654954-25-000570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000570/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:26:45.514192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}